Earlier this month, Merck and Moderna announced that their experimental melanoma treatment had succeeded in a large, late-stage clinical trial — the first time an mRNA-based cancer therapy has cleared this bar. The news sent Moderna's stock sharply higher, reviving investor interest in a company best known for its COVID-19 vaccine.

The treatment, known as intismeran autogene (also called V940 or mRNA-4157), is not a preventive vaccine in the traditional sense. It is built individually for each patient: a sample of their tumor is sequenced to identify its specific mutations, and that information is used to manufacture a personalized mRNA shot designed to train the immune system to recognize and attack the cancer. It is given alongside Merck's blockbuster immunotherapy Keytruda.

In the Phase 3 INTerpath-001 trial, more than 1,100 patients who had surgery to remove high-risk melanoma were randomly assigned to receive either the combination therapy or Keytruda alone for about a year. The companies reported that patients on the combination went significantly longer without their cancer returning, meeting the trial's main goal of improving recurrence-free survival. A key secondary measure, tracking how long patients stayed free of metastases in other parts of the body, was also met. Merck and Moderna described the safety profile as consistent with earlier studies, with no new concerns identified.

The Phase 3 result builds on years of earlier data. In the preceding Phase 2b trial, the combination cut the risk of recurrence or death by roughly half compared with Keytruda alone, and cut the risk of distant metastasis by well over half — benefits that held up when the companies presented five-year follow-up figures earlier this year. That durability is part of why analysts have been watching this program closely: cancer treatments that work well in small trials often disappoint at Phase 3 scale, and this is the first personalized neoantigen therapy of its kind to avoid that fate.